Lumito AB (publ) ("Lumito" or the "Company") announces that Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, has added Lumito's advanced tissue analysis technology to its customer offering,following a joint development collaboration leading to positive results from its evaluation of the SCIZYS platform.
"This is an important step forward in our collaboration and also fully in line with Lumito’s established strategy; collaborating with CROs who offer tissue analysis tests based on our SCIZYS technology to their clients, enabling us to generate revenues. The fact that Concept Life Sciences, an established player, not only confirms our technological strengths but also sees a clear market value is very gratifying and affirming. Their decision to integrate our technology into their offering shows the potential of our solution”, says Sanna Wallenborg, CEO of Lumito.
Lumito announced on March 27, 2025, through a press release that the Company had entered into a collaboration with Concept Life Sciences, to improve tissue analysis in drug development. The joint project focused on evaluating and optimising Lumito's technology for use in Concept Life Sciences’ research services.
Since the start of the collaboration, Concept Life Sciences has conducted a comprehensive and independent evaluation of Lumito's technology, with results showing that Lumito's solution exhibits a 10x higher sensitivity compared to established technologies on the market. In addition, as announced through a press release on August 13, 2025, Lumito's samples have proven to work fully in an autostainer, which ensures high and consistent quality in laboratory analyses. Following the technical evaluation, Concept Life Sciences conducted customer dialogues to gauge market interest. The response from customers has clearly demonstrated a need for a more sensitive and faster solution.
Concept Life Sciences has now entered the commercial phase where Lumito's solution is offered to its customers. As a consequence of the excellent sensitivity and dynamic range of the SCIZYS-platform, Lumito’s solution can be offered at a premium price compared with conventional IHC solutions. The commercial agreement is based on the ”scanning-as-a-service” model where Lumito provides a fully encompassing solution with reagents, in-house scanning and image transfer. Tissue preparation, staining and image analysis are done by Concept Life Science in its best-in-class facility in Edinburgh, Scotland.
"After testing Lumito's technology both technically and in dialogue with our customers, we see a clear market potential. The combination of high sensitivity and compatibility with our existing systems makes the solution very attractive, both from a scientific and commercial perspective. Together, we aim to make a significant difference in drug development particularly areas such as spatial biology where accurate and measurable detection of protein can be difficult," says Chris Mills, Senior Scientist at Concept Life Sciences.